US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery Market Research Reports & Industry Analysis

RSS Feeds

Drug Discovery Industry Research & Market Reports

6  7  8  9    11    13  14  15  
Post-Operative Pain Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... Post-Operative Pain in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and ...  |  read more...
USD 670
Human Papillomavirus Infections Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... emerging therapies for Human Papillomavirus Infections in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating ...  |  read more...
USD 670
Thrombosis Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing ...  |  read more...
USD 670
Alzheimer's Disease Drugs Markets in China
11/1/2014 | published by: Asia Market Information & Development Company
... The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines ...  |  read more...
USD 4,000
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... 395 Alpha6Beta4 integrin pathway targeting drugs in 1391 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 177 drugs. ...  |  read more...
USD 6,746
Apoptosis in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... cancer cells. There are today 346 companies plus partners developing 440 apoptotic drugs in 2110 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the ...  |  read more...
USD 6,746
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 213 companies plus ...  |  read more...
USD 6,746
Biologicals in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... developing 1784 biological drugs in 4104 developmental projects in cancer. In addition, there are 28 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 950 drugs. Biologicals In ...  |  read more...
USD 11,246
Bladder Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... treated early, the 5 year survival rate is 94%. There are today 101 companies plus partners developing 129 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ...  |  read more...
USD 4,496
Brain Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
USD 6,746
Cancer Drugs in the FDA Fast Lane Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... of new drugs, ranging from Fast track (1988), Accelerated approval (1992), Priority review (1992) to the most recent Breakthrough therapy (2012). This pipeline update, Cancer Drugs in the FDA Fast Lane, gives a thorough account ...  |  read more...
USD 4,496
Cancer Stem Cells Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ...  |  read more...
USD 6,746
Cellular Therapy in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... the accumulated number of ceased drugs over the last years amount to another 65 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ...  |  read more...
USD 4,496
Colorectal Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 316 companies ...  |  read more...
USD 6,746
Epigenetic Therapy in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... and to date there are several approved epigenetic drugs in oncology (eg, Azacitidine, Decitabine, Vorinostat, Romidepsin, Ruxolitinib). Today a majority of drugs targets histone methylation and acetylation, also frequently dysregulated in cancer cells, in the ...  |  read more...
USD 4,496
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ...  |  read more...
USD 6,746
Head and Neck Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 51 drugs. Head And Neck Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 6,746
Hematological Cancers Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... 796 hematological cancer drugs in 1797 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 243 drugs. Hematological Cancers ...  |  read more...
USD 8,996
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... (O(2)) and nutrient availability. The hypoxia-inducible factors (HIFs) are a common link between adaptation to low O(2), changes in cancer metabolism, and malignant progression. This report focusses around the cancer drugs targeting the hypoxia-inducible factor ...  |  read more...
USD 6,746
ID Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 94 companies plus partners developing 96 ID pathway targeting drugs in ...  |  read more...
USD 2,246
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 86 companies plus partners developing 86 IL-1 pathway targeting drugs in 332 developmental projects in cancer. In ...  |  read more...
USD 4,496
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 27 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 2,246
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 4,496
Immunotherapy in Oncology Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 595 companies plus partners developing 1158 cancer immunotherapy drugs in 3012 developmental projects in cancer. In addition, there are 19 ...  |  read more...
USD 11,025
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014
10/27/2014 | published by: BioSeeker Group AB
... well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. There are today 373 companies plus partners developing 610 cytokine-cytokine receptor interaction ...  |  read more...
USD 6,746
6  7  8  9    11    13  14  15